三生國健(688336.SH)拉昇漲近10% 股價創4個月新高
格隆匯5月26日丨中國抗體藥物先行者三生國健(688336.SH)今日再度拉昇,盤中一度漲近10%報21.57元,創1月22日以來新高,市值超130億元。該股自5月10日反彈至今,累漲36%。公司5月12日稱收到國家藥監局核准簽發的《藥物臨牀試驗批准通知書》,同意一項評價CPGJ602聯合伊尼妥單抗及化療在HER2陽性且KRAS、NRAS和BRAF野生型的轉移性結直腸癌患者中有效性和安全性的Ⅰb/Ⅱ期臨牀研究,並將於近期開展臨牀試驗。另外,公司日前宣佈投資的Numab Therapeutics完成1億瑞士法郎(約合1.1億美元)的C輪融資。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.